AzTrials
AzTrials

CaffeineNCT05230303

Caffeine Supplementation, Resistance Training and Blood Antioxidant Status

A study testing Caffeine supplementation in people with Caffeine, run by The Jerzy Kukuczka Academy of Physical Education in Katowice at 1 site in Poland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to verify the effect of acute caffeine intake on resistance training volume and blood antioxidant status, in a randomised, double-blind, placebo-controlled crossover trial. Read more about this study

Who is it for?
Ages 18 to 45 years, men onlyHealthy volunteers can take part
Conditions the study is for
Caffeine
What is being tested?
Caffeine supplementation
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
15 participants
Where
1 sitePoland
Study dates
12 Jan 2022to 31 Jan 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • written consent to participate,
  • medical permission by physician
  • "resistance-trained," defined as having a minimum of two years of resistance training experience
  • minimum of 2 workout sessions per week in the last 6 months

Who cannot join

  • neuromuscular or musculoskeletal disorders
  • current injury
  • using any medications, dietary supplements or ergogenic aids which could potentially affect the study outcomes
  • a positive smoking status
  • potential allergy to caffeine

Trial locations and contacts

1 site in 1 country.

Poland1 site
  • The Jerzy Kukuczka Academy of Physical Education

    Katowice, 40-065

Other trials in Poland

About this study

Official title: Acute Effects of Caffeine Supplementation on Resistance Training Volume and Blood Antioxidant Status in Resitance Trained Men

The purpose of this study is to verify the effect of acute caffeine intake on resistance training volume and blood antioxidant status, in a randomised, double-blind, placebo-controlled crossover trial.

Read the detailed description

Caffeine is one of the most commonly consumed psychoactive substances in the world. Several previous studies confirmed that caffeine improves several aspects of exercise performance, including resistance training outcomes. Interestingly, caffeine and its catabolic products, theobromine and xanthine, exhibit antioxidant and prooxidant properties. Additionally, resistance training promotes the generation of reactive oxygen species, which are important for the cellular adaptation process.

Hovewer, to the best of our knowledge, there is no information as to how caffeine combined with resistance training affects blood antioxidant status. Therefore, the aim of this study was to examine acute effects of caffeine supplementation on resistance training volume and blood antioxidant status in resistance trained men.

Conditions
Caffeine
Being tested
Caffeine supplementation, Placebo treatment
Keywords
sports performance, resistance training, nutrition, athlete

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Caffeine supplementationDietary supplement

    Two identical experimental sessions with a one-week interval between sessions (to allow complete recovery and ensure substance wash-out) will be taken. During the experimental sessions, participants will ingest caffeine in dose of 3 mg/kg of body mass. Caffeine will be provided in capsules containing the individual amount of caffeine and will be administered orally 60 min before the onset of the exercise protocol.

  • Placebo treatmentDietary supplement

    The experimental procedure for each particpant will include placebo supplementation. The manufacturer of the caffeine capsules will also prepare identical placebo capsules filled out with a microcrystalline cellulose. Placebo will be administered orally 60 min before the onset of the exercise protocol.

Study groups in NCT05230303
Study groupRoleWhat they receive
Caffeine supplementationExperimentalGroup taking 3 mg/kg of caffeine
Receives: Dietary Supplement: Caffeine supplementation
Placebo treatmentPlacebo comparatorGroup taking placebo
Receives: Dietary Supplement: Placebo treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change the levels of oxidative stress markers

    Serum will be obtained for TOS/TOC (total oxidative stress), MDA (malondialdehyde), oncentration of TAS (total antioxidant status), activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx); concentartion of GSH (reduced glutathione) and UA (uric acid)

    Measured: Day 1, Day 2

  2. Changes in markers of muscle damage

    Serum will be obtained for activity of creatine kinase (CK) and lactate dehydrogenase (LDH), concentration of myoglobin (Mb)

    Measured: Day 1, Day 2

  3. Changes in Inflammation markers

    Serum will be obtained for level of interleukin 6, TNF alfa (tumor matrix factor), CRP (C-reactive protein)

    Measured: Day 1, Day 2

  4. Changes in markers of liver function

    Serum will be obtained for activity of ASPAT (aspartate aminotransferase), ALAT (alanine aminotransferase) and gamma glutamyltransferase (GGT)

    Measured: Day 1, Day 2

Secondary outcomes (4)
  1. Changes in resistance training volume

    Measured: During caffeine and placebo treatment

  2. Changes in rate of perceived exertion after resistance training

    Measured: Immediately after exercise protocol during caffeine and placebo treatment

  3. Changes in heart rate during resistance training

    Measured: During caffeine and placebo treatment

  4. Changes in muscle soreness

    Measured: prior to exercise, and 24, 48, 72, 96 and 120 hours post exercise.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Feb 2022
  2. Study start12 Jan 2022
  3. Primary completion31 Jan 2023
  4. Study completion31 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
15 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05230303
Sponsor's protocol ID
01_2021
Status last verified
Mar 2023
First submitted
14 Jan 2022
Last updated
10 Mar 2023
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: We do not plan to share IPD.

Publications

  • Filip-Stachnik A, Krzysztofik M, Del Coso J, Palka T, Sadowska-Krepa E. The Effect of Acute Caffeine Intake on Resistance Training Volume, Prooxidant-Antioxidant Balance and Muscle Damage Markers Following a Session of Full-Body Resistance Exercise in Resistance-Trained Men Habituated to Caffeine. J Sports Sci Med. 2023 Sep 1;22(3):436-446. doi: 10.52082/jssm.2023.436. eCollection 2023 Sep.

    PubMed 37711718

Questions about this trial

What is this clinical trial studying?

A study testing Caffeine supplementation in people with Caffeine, run by The Jerzy Kukuczka Academy of Physical Education in Katowice at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 10 Mar 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change the levels of oxidative stress markers (time frame: Day 1, Day 2). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05230303, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Mar 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in